sulfinpyrazone has been researched along with Kidney Failure, Chronic in 8 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Starting dosage was 200 mg per day; daily dosage was then increased, every 4 days, by 200 mg or kept constant for another 4 days, according to each patient's basal renal function, up to the maintenance dose: 800 mg/day." | 1.27 | Sulphinpyrazone in cardiovascular elderly azotemic patients: a proposal of a 'guided' incremental dose schedule. ( Borghi, C; Dacco', L; Di Ruvo, R; Palummeri, E; Passeri, M, 1984) |
| " Starting dosage was 200 mg per day; daily dosage was then increased every 4 days of 200 mg, or kept constant for another 4 days, according to each patient's renal function, up to 800 mg per day." | 1.27 | [Renal tolerance of an incremental dosage regimen of anturan in the aged with altered renal function]]. ( Bertolini, G; Borghi, C; Naliato, P, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (87.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palummeri, E | 1 |
| Borghi, C | 2 |
| Di Ruvo, R | 1 |
| Dacco', L | 1 |
| Passeri, M | 1 |
| Wizemann, V | 1 |
| Buddensiek, P | 1 |
| de Boor, J | 1 |
| Grebe, S | 1 |
| Schütterle, G | 1 |
| Boelaert, J | 1 |
| Schurgers, M | 1 |
| Daneels, R | 1 |
| Lijnen, P | 1 |
| Amery, A | 1 |
| Bern, MM | 1 |
| Green, J | 1 |
| Woods, HF | 1 |
| Ash, G | 1 |
| Parsons, V | 1 |
| Weston, MJ | 1 |
| Grzegorzewska, A | 1 |
| Antoniewicz, K | 1 |
| Kuźniak, J | 1 |
| Zawadzka, E | 1 |
| Opatrný, K | 2 |
| Cepelák, V | 1 |
| Valenta, J | 1 |
| Cepeláková, H | 1 |
| Sefrna, F | 1 |
| Bertolini, G | 1 |
| Naliato, P | 1 |
1 trial available for sulfinpyrazone and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Personal experience with the administration of sulfinpyrazone to patients with kidney failure].
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Kidney Failure, Chronic; Kinet | 1986 |
7 other studies available for sulfinpyrazone and Kidney Failure, Chronic
| Article | Year |
|---|---|
Sulphinpyrazone in cardiovascular elderly azotemic patients: a proposal of a 'guided' incremental dose schedule.
Topics: Aged; Cardiovascular Diseases; Drug Administration Schedule; Drug Tolerance; Female; Humans; Kidney | 1984 |
Gastrointestinal blood loss in patients undergoing maintenance dialysis.
Topics: Adult; Aged; Aluminum Hydroxide; Female; Heparin; Humans; Kidney Failure, Chronic; Male; Melena; Mid | 1983 |
Drug-induced renal failure.
Topics: Humans; Indomethacin; Kidney Failure, Chronic; Myocardial Infarction; Sulfinpyrazone | 1982 |
Effect of sulfinpyrazone upon antithrombin III and platelet factor 4 in chronic renal failure.
Topics: Adult; Aged; Antithrombins; Blood Coagulation Factors; Female; Humans; Kidney Failure, Chronic; Male | 1982 |
Reduction of dialyzer fibrin deposition with sulphinpyrazone.
Topics: Blood Platelets; Fibrin; Fibrinogen; Humans; Kidney Failure, Chronic; Kidneys, Artificial; Sulfinpyr | 1979 |
[Effect of sulfinpyrazone on peritoneal and renal clearance in patients with chronic renal failure treated by intermittent peritoneal dialysis].
Topics: Adult; Female; Humans; Kidney; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; | 1990 |
[Renal tolerance of an incremental dosage regimen of anturan in the aged with altered renal function]].
Topics: Aged; Cerebrovascular Disorders; Coronary Disease; Creatinine; Dose-Response Relationship, Drug; Dru | 1985 |